The price tag of a potential cure for chronic hepatitis B infection: A cost threshold analysis for USA, China and Australia
Authors:
- 8 August 2021
- journal article
- research article
- Published by Wiley in Liver International
- Vol. 42 (1) , 16-25
Abstract
Background & Aims: We aim to capture the economic impact of a potential cure for chronic hepatitis B infection (CHB) in three countries (USA, China and Australia) with different health systems and epidemics to estimate the threshold drug prices below which a CHB cure would be cost‐saving and/or highly cost‐effective.Methods: We simulated patients’ hepatitis B progression, under three scenarios: current long‐term suppressive antiviral therapy, functional cure defined as sustained undetectable HBsAg and HBV DNA, and partial cure defined as sustained undetectable HBV DNA only after a finite, 48‐week treatment.Results: Compared with current long‐term antiviral therapy, a 30% effective functional cure among patients with and without cirrhosis in the USA, China and Australia would yield 17.50, 17.32 and 20.42 QALYs per patient, and 20.61, 20.42 and 20.62 QALYs per patient respectively. In financial terms, for CHB patients with and without cirrhosis, this would be cost‐saving at a one‐time treatment cost under US$11 944 and US$6694, respectively, in the USA, US$1744 and US$1001 in China, and US$12 063 and US$10 983 in Australia.Conclusion: We show that in purely economic terms, a CHB cure will be highly cost‐effective even if effective in only 30% of treated patients. The threshold price for cure is largely determined by the current antiviral drug costs, since it will replace a daily antiviral pill that is inexpensive and effective, although not curative. The likely need for combination therapies to achieve cure will also present cost challenges. While cost‐effectiveness is important, it cannot be the only consideration, as cure will provide many benefits in addition to reduced liver disease and HCC, including eliminating the need for a long‐term daily pill and reducing stigma often associated with chronic viral infection.Keywords
This publication has 25 references indexed in Scilit:
- Hepatitis B in the Female PopulationGastroenterology Clinics of North America, 2016
- AASLD guidelines for treatment of chronic hepatitis BHepatology, 2015
- Cost-Effectiveness and Cost Thresholds of Generic and Brand Drugs in a National Chronic Hepatitis B Treatment Program in ChinaPLOS ONE, 2015
- Effect of the Ebola-virus-disease epidemic on malaria case management in Guinea, 2014: a cross-sectional survey of health facilitiesThe Lancet Infectious Diseases, 2015
- Editorial Commentary:Getting Smart in How We Pay for HCV Drugs: KAOS vs CONTROLClinical Infectious Diseases, 2015
- Population Health Impact and Cost-Effectiveness of Monitoring Inactive Chronic Hepatitis B and Treating Eligible Patients in Shanghai, ChinaHepatology, 2013
- Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: Finite treatment duration unlikelyJournal of Hepatology, 2013
- Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis BJournal of Hepatology, 2011
- Adherence to Chronic Hepatitis B Treatment Guideline Recommendations for Laboratory Monitoring of Patients Who Are Not Receiving Antiviral TreatmentJournal of General Internal Medicine, 2010
- The Impact of Chronic Hepatitis B on Quality of Life: A Multinational Study of Utilities from Infected and Uninfected PersonsValue in Health, 2008